Breaking bad...proteins

Abstract

The papers by Muchtar et al and Palladini et al in this issue of Blood each reflect the progress and challenges associated with light chain (AL) treatment, which requires a delicate balance between the rapid, effective eradication of clonal plasma cells and the increased toxicity profile observed when cytotoxic therapy (usually well-tolerated in myeloma patients) is applied to individuals with AL.1,2